Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2023 | Phase II study of NE3107 in levodopa/carbidopa-treated patients with Parkinson’s disease

Joseph Michael Palumbo, MD, BioVie Inc., Carson City, NV, describes the investigation of NE3107’s safety when used in combination with levodopa and carbidopa in Parkinson’s disease (PD). This study (NCT05083260) investigated 45 patients with two aims: to look at the pharmacokinetics (PK)/ pharmacodynamics (PD) of this combination and look for the first sign of target engagement. The study showed that PK/PD was unaffected by the co-administration. 19 patients in both the study and placebo groups started in the off state, and 35% of the study group were able to be in the on state, whereas zero of the placebo group entered this state. The study witnessed an improvement in UPDRS Part 3 of 3 points in the entire study group relative to the placebo. It also saw a better improvement of about 6 points for those under 70. Moving forward, this needs to be replicated in further double-blind studies. This interview took place at the AAN Annual Meeting 2023 in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Dr Palumbo is a full-time employee of BioVie, Inc.